The same samples did not produce identical numbers
Researchers measured IGF-1 in samples from 427 healthy adults using four commercial immunoassays. The methods showed systematic differences, and the authors emphasized assay-specific reference information. This was a laboratory comparison, not a treatment trial. [1]
For someone monitoring a sermorelin prescription, the implication is practical: a numerical difference between reports may require interpretation of the measurement method as well as the person’s biology. The result should travel with the laboratory name, units and reference interval, rather than as a cropped number.
A reference interval belongs to a method
Our interpretation is that borrowing a target from another laboratory or an online chart can remove the very context needed to interpret a value. A number that appears higher on one report should not automatically be described as a treatment success or deterioration before the reports are compared properly.
This does not mean laboratory testing is unreliable or useless. It means that useful measurement has specifications. The same principle applies to a ruler with a different scale: the reading becomes meaningful when the scale is known. A clinician can decide whether the difference is interpretable or whether additional information is needed.
Separate an analytical difference from a clinical change
The study found structured differences among methods rather than random proof that every test was wrong. [1] Distinguishing those possibilities matters. If methods differ predictably, the issue is interpretation and comparability, not a reason to abandon testing or select whichever result is most reassuring.
When a report conflicts with expectations, ask whether the assay changed and whether the laboratory’s reference information changed. Do not assume that a new prescription, a missed injection or an altered routine caused the discrepancy. Several explanations may need to be considered before a treatment decision is justified.
A better record for follow-up
Keep complete reports in date order and note changes in the laboratory used. Ask the ordering clinician how comparisons will be made across visits. Our IGF-1 guide explains what the biomarker can and cannot establish, while the sampling-time example illustrates a different source of context.
A monitoring plan should specify who interprets the result and what decision it informs. It should not ask a consumer to calculate a personal dose from an internet target. Assay-comparison research makes testing more understandable precisely by showing why the full report and a clinical interpretation matter more than ranking isolated numbers.
If a service changes laboratories during follow-up, request an explanation of how that affects comparisons before interpreting the next value. Retaining the original reports also helps a later clinician reconstruct which apparent changes coincided with a measurement change.